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Abstract
Robotic assistance has gained acceptance in thoracic procedures, including esophagectomy. There is a paucity of data regarding long-term outcomes for robotic esophagectomy. We previously reported our initial series of robot-assisted Ivor Lewis
(RAIL) esophagectomy. We report long-term outcomes to assess the efficacy of the procedure. We performed a retrospective
review of 112 consecutive patients who underwent a RAIL. Patient demographics, diagnosis, pathology, operative characteristics, post-operative complications, and long-term outcomes were documented. Descriptive statistical analysis was performed
for all the variables. Primary endpoints were mortality and disease-free survival. Overall survival (OS) and disease-free
survival (DFS) were calculated using the Kaplan–Meier method. Of the 112 patients, 106 had a diagnosis of cancer, with
adenocarcinoma the dominant histology (87.5%). Of these 106 patients, 81 (76.4%) received neo-adjuvant chemoradiation.
The 30-, 60-, and 90-day mortality was 1 (0.9%), 3 (2.7%), and 4 (3.6%), respectively. There were 9 anastomotic leaks (8%)
and 18 (16.1%) patients had a stricture requiring dilation. All-patient OS at 1, 3, and 5 years was 81.4%, 60.5%, and 51.0%,
respectively. For cancer patients, the 1-, 3-, and 5-year OS was 81.3%, 59.2%, and 49.4%, respectively, and the DFS was
75.3%, 42.3%, and 44.0%. We have shown that long-term outcomes after RAIL esophagectomy are similar to other nonrobotic esophagectomies. Given the potential advantages of robotic assistance, our results are crucial to demonstrate that
RAIL does not result in inferior outcomes.
Keywords Survival · Esophageal cancer · Esophagectomy · Robotic · Ivor Lewis

Introduction
Esophageal cancer is the sixth leading cause of cancerrelated deaths worldwide [1]. Surgery remains the mainstay of treatment. There are different types of surgery
offered to patients, and each with its own set of advantages
and disadvantages [2, 3]. One technique is the Ivor Lewis
esophagectomy, the most commonly employed technique for
esophagectomy.
Minimally invasive esophagectomy (MIE) has gained
widespread acceptance. In fact, there was a threefold
increase in the preference of MIE among surgeons between
2007 and 2014 [4]. Initially, MIE was performed using
thoracoscopy, but the use of robotic assistance has been
increasing [5]. Robotic assistance offers several advantages

over thoracoscopic or open approaches, including better visualization and increased degrees of freedom [6]. Short-term
studies have shown that robotic-assisted Ivor Lewis (RAIL)
has similar outcomes to open and thoracoscopic esophagectomies [7]. A recent randomized controlled trial showed
better post-operative outcomes with a robotic approach
compared to an open approach, with comparable oncologic
results [8]. Notably, the surgical approach in their series was
the McKeon or three port technique. However, long-term
outcomes of RAIL esophagectomy are lacking.
In an attempt to elucidate the long-term outcomes of
RAIL, we examined our own series of patients. We examined both short- and long-term outcomes, with particular
emphasis on long-term survival after RAIL esophagectomy.

Methods
* Zane Hammoud
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Department of Surgery and Division of Thoracic Surgery,
Henry Ford Health System/Wayne State University, 2799 W.
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After institutional approval, a retrospective chart review of
patients who underwent a RAIL esophagectomy between
2011 and 2018 was performed. Demographic information

13

Vol.:(0123456789)

Journal of Robotic Surgery

including age, sex, body mass index (BMI), and co-morbidities was collected. Procedure information collected included
operative time and estimated blood loss. Oncologic variables
gathered included tumor type, tumor stage, administration
of neoadjuvant therapy, margins after resection, number of
nodes collected, and number of positive nodes.
The details of the surgical operation were described
previously [9]. All surgeries were performed by a single
surgeon (ZTH who has performed greater than 500 robotic
procedures). In brief, we perform laparoscopic gastric mobilization and creation of the gastric conduit. Most patients
underwent laparoscopic injection of 200 units of botulinum
toxin into the pylorus. This is followed by robotic transthoracic esophagectomy with an intrathoracic anastomosis
above the level of the azygous vein. Robotic surgery was
performed using the DaVinci system Si and Xi (Intuitive
Surgical, Inc. Sunnyvale, CA). Our anastomotic technique
utilizes a linear stapler for the posterior wall while the front
wall is manually sutured using a combination of 3-0 Vicryl
and 3-0 Stratafix suture in two layers (Ethicon, Inc., Somerville NJ). In all cases, we utilize indocyanine green to assess
conduit and esophageal perfusion using the robotic Firefly
technology.
Patients are extubated in the operating room at the conclusion of the surgery. Feeds through a jejunostomy tube are
initiated within 24–48 h after surgery. We perform esophagram on post-operative day 5 or 6. If this is without evidence
of anastomotic leak, we remove the nasogastric tube and
oral intake is initiated. Patients are discharged on average
7–10 days after surgery.
Post-operative complications were documented. These
included arrhythmias, anastomotic leaks, myocardial infarction, pneumonia, ventilator-dependent respiratory failure,
reintubation, acute renal failure, surgical-site infection,
pleural effusion, chylothorax, deep vein thrombosis, and
stroke. Longer-term complications, such as anastomotic
stricture requiring dilation and delayed gastric emptying at
12 months, were documented as well. All-cause mortality,
cancer-specific mortality, and disease-free survival were
examined for all patients.
Descriptive analysis was performed for all variables.
Continuous variables are described by mean and categorical variables described by proportions. Survival curves were
calculated using the Kaplan–Meier Method. All statistical
analyses were performed using R, version 3.5.1.

Results
Between 2011 and 2018, all patients who are candidates for
an Ivor Lewis esophagectomy were approached with RAIL
(112 total patients). Indication for surgery was cancer in 106
(94.6%) patients. Patient characteristics are summarized in

13

Table 1  Patient demographics
Patient characteristic

Number of patients

Age (Mean [SD])
Male
BMI (Mean [SD])
Neoadjuvant therapy
Smoking history
Pre-operative albumin (Mean [SD])
Hypertension
Coronary artery disease
Diabetes
Gastroesophageal reflux disease
COPD
Pre-operative J feeding tube
Pre-operative G feeding tube
Pre-operative dysphagia

64.1 [9.3]
89
27.4 [5.6]
81
84
3.68 [0.46]
58
18
32
54
18
15
3
81

%
84.0
76.4
79.2
54.7
17.0
30.2
50.9
17.0
14.2
2.7
76.4

Table 2  Tumor type
Histologic type

Number of patients

%

Adenocarcinoma
Squamous cell carcinoma
High grade dysplasia
Other

98
3
2
9

87.5
2.68
1.79
8.04

Table 1. The mean age was 64.1 [SD 9.3] years. Eighty-nine
(84.0%) patients were male. Most had a history of smoking (79.2%), and a majority had a history of hypertension
(54.7%). Other co-morbidities included coronary artery disease (17.0%), diabetes (30.2%), GERD (50.9%), and COPD
(17.0%). Most patients (76.4%) reported pre-operative dysphagia. Eighty-one (76.4%) received neoadjuvant chemoradiotherapy, and 18 (16.9%) had either a pre-operative
gastrostomy or jejunostomy. Tumor characteristics are summarized in Table 2.
The mean operative time was 357 min (range 256–582).
As expected, operative times decreased over time, with a
mean time of 346 min over the last 30 cases, compared to a
mean of 364 min for the cases prior. The average blood loss
was 64.6 ml. The mean number of nodes harvested was 19
(range 2–48). The median number of positive nodes was 0
(range 0–16). All patients had an R0 resection. The clinical
and pathologic staging of the cancer patients is summarized
in Table 3. Nineteen (19.8%) patients had pathologic complete response (pCR) and one patient (1.0%) had M1 disease.
Table 4 describes postoperative complications (with
Clavien–Dindo grade). The most common complication was arrhythmia (28.3%). Pneumonia occurred in 11
(10.4%) patients, 14 (13.2%) patients required reintubation, and 14 (13.2%) had a pleural effusion. Nine (8.5%)
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Table 3  Staging of cancer patients
Pathology
Clinical staging
T1 N0
T2 N0
T3 N0
T1 N1
T2 N1
T3 N1
T2 N2
T3 N2
T2 Nx
T3 Nx
T4 Nx
M1
Pathologic staging
pCR
T0 N1
T0 N2
T1 N0
T2 N0
T3 N0
T1 N1
T2 N1
T3 N1
T3 N2
T4 N2
T2 N3
T3 N3
T3 N0 M1

Table 4  Postoperative complications
Number of patients

%

8
5
23
1
6
38
2
3
2
4
1
2

8.4
5.3
24.2
1.1
6.3
40.0
2.1
3.2
2.1
4.2
1.1
2.1

19
1
1
24
12
13
6
2
6
6
1
1
3
1

19.8
1.0
1.0
25.0
12.5
13.5
6.3
2.1
6.3
6.3
1.0
1.0
3.1
1.0

patients experienced an anastomotic leak, one of whom
required re-operation. The remaining 8 patients were managed by endoscopically placed covered esophageal stents
and all recovered uneventfully, with stent removal approximately 3 weeks after initial placement. Seventeen (16.0%)
patients experienced an esophageal stricture that required
dilation on long-term follow-up. Seven patients (6.6%) had
delayed gastric emptying at 6 months (based on clinical
and/or radiographic evidence), and 3 patients (2.8%) had
delayed gastric emptying at 12 months.
The 30-, 60-, and 90-day mortality was 1 (0.9%), 3
(2.8%), and 4 (3.8%), respectively. Overall survival of all
patients at 1, 3, and 5 years was 81.4%, 60.5%, and 51.0%,
respectively. Figure 1 shows the overall and disease-free
survival of the 106 cancer patients. For these patients,
the 1-, 3-, and 5-year overall survival was 81.3%, 59.2%,
and 49.4%, respectively, and the disease-free survival was
75.3%, 42.3%, and 44.0%.

Postoperative complication

Number
%
of patients

Arrythmia
Anastomotic leak
Stricture
Myocardial infarction
Pneumonia
Vent dependent respiratory failure
Reintubation
Acute renal failure
Surgical site infection
Pleural effusion
Chylothorax
Deep vein thrombosis
Stroke
Delayed gastric emptying—6 monthsa
Delayed gastric emptying—12 monthsa
30-day mortality

30
9
17
0
11
10
14
5
4
14
2
3
0
7
3
1

a

ClavienDindo
grade

28.3
8.5
16.0
0.0
10.4
9.4
13.2
4.7
3.8
13.2
1.9
2.8
0.0
6.6
2.8
0.9

2
3

2
4a
4a
1
1
1
2

5

Rate among surviving patients

Discussion
The use of robotic assistance in a wide variety of surgical
procedures has steadily increased and been widely accepted.
While there have been multiple reports of short-term efficacy and safety, there is a paucity of data regarding longterm outcomes of robotic-assisted surgery. This is particularly true in RAIL esophagectomy. We sought to assess the
long-term outcomes of RAIL esophagectomy performed at
our institution to determine whether robotic assistance is
equivalent to other techniques, particularly with respect to
oncologic outcomes. To our knowledge, this is the largest
such series reported, with 112 consecutive cases performed
in a single institution. Of these, 106 were performed for a
diagnosis of cancer. Not surprisingly, the majority of these
patients had adenocarcinoma. Also, consistent with current
practice, the majority of our cancer patients presented with
locally advanced disease and received neo-adjuvant chemoradiation therapy.
Oncologic outcomes are an important measure of oncologic surgery, and RAIL is no exception. We collected a
mean of 19 lymph nodes throughout our series (range of
2–48), consistent with other reports in the literature [10–14].
All patients in our series had an R0 resection. At minimum,
this indicates that robotic assistance did not result in any
compromise of surgical margin. No patient in this series
incurred a local recurrence of their cancer.
Operative time and estimated blood loss are often used
as a metric when comparing surgical approaches. Weksler
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Fig. 1  Overall and disease-free
survival of cancer patients. OS
overall survival, DFS diseasefree survival

et al. found no significant difference in the average operative time between MIE and a robotic-assisted esophagectomy [7]. Shridhar et al. studied 89 patients that underwent
a RAIL esophagectomy and compared differences between
patients that received neoadjuvant radiation and those that
did not and found similar operative time and blood loss
between the two groups [15]. In our series, the average
operative time was 357 min and the average estimated
blood loss was 64.6 ml. Our lower operative time may be
secondary to utilizing the robot only for the intrathoracic
portion of the surgery. We believe that the operative time
would increase significantly if we were to utilize the robot
for both portions, as the docking and undocking multiple
times requires additional time. This is further supported
by the findings of Puntambekar et al., who also utilize the
robot for the intrathoracic portion, and use a laparoscopic
approach for the intraabdominal portion of the surgery
[16]. Kernstine et al. reported eight cases utilizing the
robot for the entire procedure with a mean operative time
of 11.1 h [17].

13

Another important measure of long-term outcome in
esophagectomy is the development of anastomotic stricture.
Strictures can be detrimental as they can lead to a decrease
in the quality of life [18]. In our series, 16% of patients
developed a stricture that required at least one dilation. This
is considerably lower than the 23–42% of stricture rates
reported in literature after an open esophagectomy [19, 20].
The rates of anastomotic strictures vary substantially after
a robotic-assisted esophagectomy and can be between 10
and 68% [13, 21]. We believe our anastomotic technique
described previously results in a lower stricture rate compared to the more common end to end anastomosis (EEA).
However, we fully acknowledge that we do not have comparative data for this claim.
Delayed gastric emptying is a functional outcome of particular interest as it can increase the risk of aspiration and
morbidity as well as decrease quality of life [22]. In our
study, we found rates of 6.6% and 2.8% for delayed gastric
emptying at 6 and 12 months, respectively. After an open
esophagectomy, the rate of delayed gastric emptying can be
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as high as 40% [23]. Glatz et al. performed a matched case
analysis comparing minimally invasive esophagectomies to
open procedures [24]. In the immediate post-operative setting, they found an overall rate of 17% for delayed gastric
emptying. Interestingly, they found an increased incidence
of delayed gastric emptying in the minimally invasive group
(23% vs 10%, p = 0.042) [24]. Zhang et al. found a delayed
gastric emptying rate of 18.2%, and about 15% [25]. Our
results indicate that a RAIL esophagectomy is comparable
to open or MIE in rates of delayed gastric emptying. It is
important to note, however, that direct comparisons are difficult due to wide practice variations with regard to drainage
procedures. Our practice has moved away from pyloroplasty
as we did not note a decrease in gastric emptying issues in
our patients (data not shown).
Recent studies have shown perioperative mortality after
an esophagectomy can be lower than 2% [26]. Fuchs et al.
demonstrated that high hospital volume for the procedure
led to lower mortality [26]. Luketich et al. examined 30-day
mortality in a review of over 1000 patients after MIE and
found a rate of 1.68% [27]. Seesing et al. performed a propensity matched analysis comparing mortality between
open and minimally invasive esophagectomies, and found
no difference in the rates of 30-day mortality (3.0% vs 4.7%,
p = 0.209) [28]. These results indicate that perioperative
mortality after an MIE is comparable to open esophagectomies. Espinoza-Mercado et al. compared open, minimally
invasive, and robotic approaches and found no significant
difference in 30-day mortality [29]. He et al. showed a 0%
90-day mortality after a robotic-assisted esophagectomy
while a matched analysis showed no difference in mortality
when compared to a thoracoscopic approach [30]. In our
study, the 30-day mortality rate was 0.9% and a 90-day mortality of 3.8%, figures consistent with other reports.
Arguably, the most important outcome of any procedure
performed for a diagnosis of cancer is long-term survival,
both overall as well as disease-free survival. Incorporation of surgery into the treatment of localized esophageal
cancer leads to improved survival [31]. This benefit is further enhanced with the addition of neoadjuvant therapy.
The CROSS trial found a significant increase in the rates
of R0 resection with the addition of neoadjuvant therapy
(92% vs 69%, p < 0.001) [32]. A long-term analysis of the
CROSS trial found a significant increase in overall survival at 5 years (33% vs 47%) with the addition of neoadjuvant therapy [33]. We have shown a 5-year overall
survival of 49.4% and a 5-year disease-free survival of
44.0%. These findings are similar to those of others [10].
In addition, our survival rates are comparable to thoracoscopic MIE data. Woodard et al. reported a 5-year overall
survival rate of 53.9% after a hybrid minimally invasive
Ivor Lewis esophagectomy [34]. Lubbers et al. found a
5-year overall survival and disease-free survival rates of

51% and 55%, respectively, after a totally minimally invasive esophagectomy after neoadjuvant chemoradiotherapy
[35]. Tapias et al. compared open and minimally invasive
Ivor Lewis esophagectomy after neoadjuvant therapy and
found no significant difference in survival between the two
approaches [36].
Our study has several limitations. It is a retrospective
study from a single institution. There was no selection
process for the procedure and all patients brought to surgery were approached in the same manner. However, we
made the decision to present consecutive patients, as no
patients in the series were converted to any other procedure. Furthermore, it is difficult to perform any sub-group
analyses given the size of our study. Similar to other case
series, we do not have a control group. We also did not
examine financial data to determine whether robotic assistance results in additional cost. While cost is an important
consideration, it was not the aim of our study. Most, if
not all, of the limitations of our study can be overcome in
future studies by performing large multi-institution randomized controlled trials. However, we are fully aware of
the difficulties in conducting such a trial. Finally, we do
not have a direct comparison to our own thoracoscopic
or open approaches as the number of patients undergoing
these approaches is very small in our experience.

Conclusion
In conclusion, we continue to demonstrate the feasibility and
safety of a RAIL esophagectomy through examination of
long-term outcomes, including oncologic outcomes. Though
we do not offer a direct comparison with more conventional
approaches, we do believe that the RAIL esophagectomy is
a valid alternative. However, large multi-center randomized
controlled trials are warranted to measure the differences, if
any, between approaches to an esophagectomy.
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